Healthcare / Medical DevicesStockholm
$92.80
-0.10 (-0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-101.7M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
103.1x
↑EV/EBITDA
55.3x
↑ROE
-2.4%
↓Gross Margin
80.6%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+25.5%
FCF CAGR
—
FCF margin
-24.8%
FCF / Net income
7.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $250.5M · net income $-8.4M · FCF $-62.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $250.5M | $250.5M | $216.9M | $169.3M | $126.6M |
| Net Income | $-8.4M | $-8.4M | $-61.5M | $-53.6M | $-46.0M |
| EBITDA | $27.5M | $27.5M | $-26.4M | $-40.5M | $-43.7M |
| EPS | -0.51 | -0.51 | -3.75 | -3.31 | -2.89 |
| Gross Margin | 80.6% | 80.6% | 79.6% | 85.5% | 81.7% |
| Operating Margin | 4.6% | 4.6% | -28.9% | -33.3% | -43.3% |
| Net Margin | -3.4% | -3.4% | -28.4% | -31.7% | -36.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.17 | 0.19 | 0.05 |
| Current Ratio | 2.90 | 2.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-62.0M | $-62.0M | $-127.6M | $-101.7M | $-66.3M |
| Returns | |||||
| ROE | -2.4% | -2.4% | -17.6% | -13.9% | -10.7% |
| Valuation | |||||
| P/E | 103.11 | 103.11 | — | — | — |
| EV/EBITDA | 55.30 | 55.30 | — | — | — |
| P/B | 4.36 | 4.36 | 5.61 | 3.44 | 2.86 |
| Growth & Yield | |||||
| Revenue Growth | 15.5% | 15.5% | 28.1% | 33.7% | — |
| EPS Growth | 86.4% | 86.4% | -13.3% | -14.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.75 → -0.51
Residual
-7.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.